What society is getting from drug innovation
The question confronting health systems is not whether drug innovation works. It does. The question is what incremental advances deliver relative to what they cost. For many common diseases, baseline care is already highly effective, the result of decades of cumulative progress. New therapies increasingly build on that success rather than replace failure. As medicine approaches biological limits, gains are more often incremental, while prices continue to reflect the economics of earlier breakthroughs.
This reassessment is no longer theoretical. In Europe, strained public finances, rising defence commitments and renewed industrial policy have sharpened competition for scarce capital. Decisions that used to be outside the political arena are now explicitly political. In its starkest form, the trade-off increasingly resembles one between drugs or bullets. The language may be blunt, but the arithmetic behind it is unavoidable.
Healthcare spending per capita in 2022, USD
Source: KFF analysis of National Health Expenditure (NHE)
Oncology illustrates how the economics of progress have shifted. In early breast cancer, outcomes with existing therapies are already very positive, reflecting advances in surgery, radiotherapy, endocrine treatment and targeted drugs. For patients at higher risk of recurrence, the addition of CDK 4/6 inhibitors – drugs that slow tumour growth by blocking the cell division cycle – has become standard, delivering a material reduction in recurrence on top of endocrine therapy.
The latest advance, an oral selective oestrogen receptor degrader presented at the 2025 San Antonio Breast Cancer Symposium, refines this already intensive baseline. When layered onto contemporary treatment, it appears to prevent roughly three additional invasive recurrences per hundred women treated over the first few years of follow up.
US healthcare spending growth compared to GDP growth by decades, average %
Source: KFF analysis of National Health Expenditure (NHE)
That gain is clinically real. But it comes at a high cost. These benefits are delivered on top of multiyear combination therapy that already entails substantial cost, toxicity and monitoring. In high income markets, lifetime treatment costs can approach seven figures per patient. The issue is therefore not whether progress is being made, but what society gains, in aggregate, from adding successive layers of treatment to regimens that are already both effective and expensive.
Health systems are responding in different ways. In Europe, where healthcare is predominantly publicly funded, adjustment takes the form of slower access, narrower indications and more stringent health technology assessments. In the US, the response is more explicit. Moves to reference international prices, tighten Medicaid reimbursement and compel pharmacy benefit managers to pass through rebates signal a structural shift. The US is no longer prepared to underwrite global pharmaceutical research without constraint.
The outcomes differ in form, not in substance. Europe rations implicitly, trading speed for affordability. The US risks stratification, as pricing pressure in public programmes concentrates the most advanced care among those with the most generous employer sponsored insurance. The upshot is that national systems that were once handling this problem in their own way now seem to be reaching the same conclusion: even highly effective healthcare cannot be treated as an unlimited entitlement.
Deploying innovation
Focusing on price alone, however, misdiagnoses the problem. The deeper issue is how innovation is deployed. Health systems remain oriented towards treating disease late and intensively, even as marginal gains diminish. As long as this persists, costs will continue to outweigh the benefits.
Diagnostics and monitoring offer a partial corrective. Minimal Residual Disease (MRD) testing, for example, marks a shift from blanket treatment to biologically guided intervention. By detecting molecular evidence of recurrence long before clinical relapse, MRD monitoring can identify patients who genuinely benefit from prolonged, intensive therapy while sparing others unnecessary exposure.
In its starkest form, the trade-off increasingly resembles one between drugs or bullets.
Artificial intelligence reinforces this reorientation, though its impact is likely to be incremental rather than revolutionary. The first phase is already evident. AI improves productivity: refining patient selection in clinical trials, reducing protocol amendments, accelerating recruitment and lowering the cost of evidence generation. In commercial operations, it sharpens targeting, supports indication-level pricing discipline and reduces leakage across manufacturing, logistics and reimbursement. These gains are incremental but cumulative, improving returns on capital in an environment where price growth is constrained.
A second phase of AI deployment is now emerging. As AI integrates more deeply with biological data, it may reshape how disease is defined and intercepted. Pattern recognition across genomics, proteomics and longitudinal clinical records could enable earlier diagnosis, finer risk stratification and more rational deployment of therapy. Rather than layering treatment late in disease, AI enabled biology would shift care upstream, where intervention is less costly and outcomes more durable. If realised, this would not merely improve efficiency at the margin; it could fundamentally alter the trajectory of healthcare spending.
Where innovation delivers the clearest aggregate gains varies by disease. In common chronic conditions, prevention and early intervention offer the largest returns. In orphan diseases – rare, often chronic or life-threatening illnesses affecting a small percentage of the population – the calculus is different. Here, innovation often delivers transformative benefits to small groups at a high per patient cost. The trade-off is explicit but contained: high prices fund research that would otherwise not occur, while aggregate budget impact remains manageable. In this sense, orphan drugs – treatments targeted at these rare diseases – represent one of the more coherent alignments between clinical value, economic logic and social consent.
Metabolic disease sits between these poles. Newer weight loss therapies carry headline prices that appear high when viewed narrowly as chronic prescriptions. Yet obesity is a gateway condition, associated with costly to treat conditions such as diabetes, cardiovascular disease, renal failure and musculoskeletal care. If sustained weight reduction reduces the incidence or severity of these conditions, the cumulative savings – from fewer hospitalisations, procedures and complications – are likely, over time, to exceed the upfront drug spend. In this context, prevention is not an ethical argument but a balance sheet one.
Affordable outcomes
This alignment between societal value and economic return is increasingly visible in capital markets. Companies whose products reduce the future burden of particular diseases, lower intensity of care or enable precision deployment are more likely to see lower capital costs. Markets are signalling a preference for innovation that scales economically as well as clinically.
For investors, the implication is straightforward. The highest returns will accrue not to innovation in the abstract, but to innovation that countries are both willing and able to pay for. As governments weigh healthcare against defence, energy and industrial policy, products that demonstrably lighten the future burden on health systems will secure access, pricing power and longevity. In the next phase of healthcare, economic relevance will be the most reliable source of excess return.
The author
Adrien Brossard, Senior Equity Analyst
